ArticleCancer microenvironment : official journal of the International Cancer Microenvironment Society2014
T cell avidity and tumor immunity: problems and solutions.
Article in Cancer microenvironment : official journal of the International Cancer Microenvironment Society, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma.Oncoimmunology · 2022Article
- Mechanisms that allow vaccination against an oncolytic vesicular stomatitis virus-encoded transgene to enhance safety without abrogating oncolysis.Scientific reports · 2021Article
- RNA-electroporated T cells for cancer immunotherapy.Oncoimmunology · 2020Review
- Potentiating the Antitumor Activity of Cytotoxic T CellsFrontiers in immunology · 2020Article
- Polyphenols as Immunomodulatory Compounds in the Tumor Microenvironment: Friends or Foes?International journal of molecular sciences · 2019Review
- Safety and Tolerability of Adoptive Cell Therapy in Cancer.Drug safety · 2019Review
- Low Avidity T Cells Do Not Hinder High Avidity T Cell Responses Against Melanoma.Frontiers in immunology · 2019Article
- Heterogeneity assessment of functional T cell avidity.Scientific reports · 2017Article
- To affinity and beyond: harnessing the T cell receptor for cancer immunotherapy.Human vaccines & immunotherapeutics · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
A potent T cell response is an important component of durable anti-tumor immunity. The quality of the T cell response can, in-part, be measured by the avidity of the T cell for its tumor antigen-expressing target. While convention suggests that raising the avidity of the responding T cells may make for a more potent anti-tumor immune response, the threshold for effective tumor immunity remains unclear, as do some of the adverse effects of an inappropriately high avidity response. In this review, we discuss the relationship between T cell avidity and anti-tumor immunity, considering both experimental model systems as well as human clinical trials.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.